Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM : Marketing Authorization Granted for Lutathera« Injection in Japan - The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumorsá(FUJIFILM Toyama Chemical)

06/23/2021 | 03:23am EDT

TOKYO, June 23, 2021-FUJIFILM Toyama Chemical Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Junji Okada; hereinafter 'FUJIFILM Toyama Chemical') today received marketing authorization in Japan for Lutathera® Injection (INN: lutetium (177Lu) oxodotreotide) (hereinafter 'Lutathera') for the treatment of somatostatin receptor-positive neuroendocrine tumors*1.
Lutathera is a peptide receptor radionuclide therapy (PRRT), a type of radioligand therapy (RLT)*2, and was approved as the first PRRT drug in Japan.

Neuroendocrine tumors originate in neuroendocrine cells that secrete hormones and peptides. Tumors frequently develop in a variety of organs throughout the body, in particular, the pancreas, gastrointestinal tract, and lungs. Because of its limited options for drug therapy, the disease is considered to have high unmet medical needs. PRRT is widely used in many countries, as there is a need for additional effective treatment options for patients with neuroendocrine tumors.
In 2015, FUJIFILM Toyama Chemical concluded a licensing agreement with Advanced Accelerator Applications International S.A. (hereinafter 'AAA'), a Novartis company, for the domestic development and marketing of Lutathera®*3. FUJIFILM Toyama Chemical has confirmed the drug's efficacy and safety in Japanese patients through a phase I clinical study and a phase I/II clinical study, and filed an application for marketing authorization approval in 2020.

Lutathera is a therapeutic radiopharmaceutical product in which a somatostatin analog is radiolabeled with lutetium-177. It binds to somatostatin receptors that are highly expressed in neuroendocrine tumors, and directly targets cancer cells with radiation released from lutetium-177.
FUJIFILM Toyama Chemical will work to make PRRT accessible to patients in Japan by offering Lutathera. Along with Lutathera, the company also obtained domestic marketing authorization for LysaKare® Injection (hereinafter 'LysaKare') *4, an amino acid infusion solution used in combination with Lutathera for reduction of renal (kidney) radiation exposure during therapy with Lutathera. Both products are planned to be launched shortly in Japan.

By adding a therapeutic radiopharmaceutical product, Lutathera, to OctreoScan® Injection Kit*5 (for the preparation of indium (111In) pentetreotide injection fluid), a diagnostic radiopharmaceutical agent for neuroendocrine tumors already marketed, FUJIFILM Toyama Chemical will expand its offerings of comprehensive solutions for patients with neuroendocrine tumors , from diagnosis to treatment.

FUJIFILM Toyama Chemical will continue to contribute to enhancing medicine even further by delivering high value-added drugs.

Disclaimer

Fujifilm Holdings Corporation published this content on 23 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2021 07:22:03 UTC.


ę Publicnow 2021
All news about FUJIFILM HOLDINGS CORPORATION
09/22FUJIFILM : The premium compact digital camera “FUJIFILM X100V” wins Bronze Awa..
PU
09/21APPILI THERAPEUTICS : Announces Agreement with FUJIFILM and Funding Support for Clinical T..
AQ
09/21FUJIFILM : Two Fujifilm Leaders Recognized as “Women Worth Watching” by Profil..
AQ
09/21FUJIFILM : North America Corporation Celebrates Newest FUJIFILM Creators
AQ
09/20APPILI THERAPEUTICS : Up 1% as Secures US$1 Million from FUJIFILM to Support Clinical Tria..
MT
09/20APPILI THERAPEUTICS : Secures US$1 Million from FUJIFILM to Support Clinical Trials for An..
MT
09/06FUJIFILM : Launches LTO Ultrium9 Data Cartridge -Magnetic tape storage media with maximum ..
PU
09/02Peptidream to Acquire Fujifilm Toyama Chemical's Radiopharmaceutical Business
MT
09/02FUJIFILM : launches FUJINON Lens GF35-70mmF4.5-5.6 WRá(Fujifilm)
PU
09/02FUJIFILM : launches mirrorless digital camera “FUJIFILM GFX50S II”á(Fujifilm)
PU
More news
Financials
Sales 2022 2 499 B 22 561 M 22 561 M
Net income 2022 172 B 1 557 M 1 557 M
Net Debt 2022 228 B 2 062 M 2 062 M
P/E ratio 2022 22,7x
Yield 2022 1,09%
Capitalization 3 915 B 35 363 M 35 349 M
EV / Sales 2022 1,66x
EV / Sales 2023 1,60x
Nbr of Employees 73 275
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 9 792,00 JPY
Average target price 10 057,14 JPY
Spread / Average Target 2,71%
EPS Revisions
Managers and Directors
Teiichi Goto President, CEO & Representative Director
Kenji Sukeno Chairman
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION80.07%35 363
ABBOTT LABORATORIES13.59%220 485
MEDTRONIC PLC11.00%174 982
BECTON, DICKINSON AND COMPANY1.18%72 711
HOYA CORPORATION30.69%62 143
ALIGN TECHNOLOGY, INC.35.72%57 302